Therapeutic use of anti-tf-antigen antibody

Abstract

The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF—Ag, or for detection of tumors or metastatic foci which express TF—Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF—Ag, the method comprises administering to the individual a therapeutic amount of mAb JAA-F11, wherein the JAA-F11 mAb inhibits the metastasis and/or growth of the TF—Ag expressing cancer cells. For detection of tumors or metastatic foci, mAb JAA-F11 is conjugated to a detectable label and administered to the individual. Detection of the label identifies metastatic foci or tumors which comprise cancer cells expressing TF—Ag.

1 . A method for identifying metastatic foci or one or more tumors in an individual, wherein the metastatic foci or the one or more tumors comprise cells expressing TF—Ag, comprising the steps of:
 a) administering to the individual monoclonal antibody JAA-F11, wherein the monoclonal antibody JAA-F11 has been conjugated to a detectable label; and   b) detecting the detectable label to identify the metastatic foci or one or more tumors.   
     
     
         2 . The method of  claim 1 , wherein the detectable label is selected from the group consisting of iodine 123 , iodine 131 , iodine 124 , indium 111  and fluorine 19 . 
     
     
         3 . The method of  claim 1 , wherein detecting the detectable label is performed by magnetic resonance imaging or single photon emission computed tomography. 
     
     
         4 . The method of  claim 1 , wherein the one or more tumor or the metastatic foci comprise cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and pancreas cancer cells.